PHARMACEUTICAL INDUSTRY DEVELOPMENT: KEY POLICY INSTRUMENTS IN CHINA
Abstract
The article provides an overview of programs, plans, tools of scientific and technological, innovation and industrial policy aimed at creating and producing new drugs in China; it is substantiated that the Chinese government uses an integrated approach in the implementation of mechanisms to protect and strengthen the pharmaceutical industry. It is demonstrated that the Chinese government provides business support in the form of subsidies, tax incentives, the creation of special zones for the development of high-tech industries, and helps to attract foreign direct investment in contract manufacturing and research and development, accompanied by technology transfer; through the public procurement system, a program for the development of endogenous innovations is implemented through the provision of price preferences, and advanced foreign technologies are involved. State support contributed to an increase in the level of localization of production and an increase in the number of jobs, an increase in the added value of production and the competitiveness of the pharmaceutical industry, the formation of scientific and technical competencies and the development of technologies, the creation of objects of intellectual property rights. The Chinese model of investment and innovative development, relying on the use of external technological, production, human resources, has made it possible to form a high-tech pharmaceutical sector capable of producing endogenous innovations. Given the objectives of the policy documents, Chinese enterprises are encouraged to invest in other countries in the interests of the development of Chinese pharmaceuticals.
Downloads
References
World Economic Outlook Update (2020). A Crisis Like No Other, An Uncertain Recovery. Available at: https://www.imf.org/en/Publications/WEO/Issues/2020/06/24/WEOUpdateJune2020
Schwarz, P. (2020). European Union to spend half a trillion euros on imperialist interests in coronavirus bailout. World Socialist Web Site. Available at: https://www.wsws.org/en/articles/2020/04/13/euro-a13.html
Science and Engineering (2020). The State of U.S. Available at: https://ncses.nsf.gov/pubs/nsb20201/data
The Indian pharmaceutical industry – the way forward (2019). Mumbai. Available at: https://www.ipa-india.org/static-files/pdf/publications/position-papers/2019/ipa-way-forward.pdf
Ni, J., Zhao, J., Ung, C. O. L., Hu, Y., Hu, H., Wang, Y. (2017). Obstacles and opportunities in Chinese pharmaceutical innovation. Globalization and Health, 13 (1). doi: http://doi.org/10.1186/s12992-017-0244-6
Bartlett, C. A., Ghosal, S. (2000). Going global: lessons from late movers. Harvard Business Review, 78 (2), 132–142.
Hu, H., Zhang, L. (2015). Catch-Up of Chinese Pharmaceutical Firms Facing Technological Complexity. International Journal of Innovation and Technology Management, 12 (4), 1550017. doi: http://doi.org/10.1142/s0219877015500170
Lei, J., Lin, B., Sha, S. (2016). Catching-Up Pattern Among Countries in Science-Based Industries: A Case Study in Pharmaceutical Industry. Journal of Industrial Integration and Management, 1 (1), 1650004. doi: http://doi.org/10.1142/s2424862216500044
Jingxi, D., Yajiong, X., Huigang, L., Rong, S., Yongfa, C. (2011). From Imitation to Innovation: A Study of China’s Drug R&D and Relevant National Policies. Journal of Technology Management & Innovation. Santiago, 6 (2), 1–13. doi: http://doi.org/10.4067/s0718-27242011000200001
Zhao, J. (2015). International Market Entry Modes. Advances in Human Resources Management and Organizational Development, 225–253. doi: http://doi.org/10.4018/978-1-4666-7332-8.ch011
Salikhova, O. B. (2012). Vysokotekhnolohichni vyrobnytstva: vid metodolohii otsinky do pidnesennia v Ukraini. Kyiv: NAN Ukrainy, Instytut ekonomiky ta prohnozuvannia, 624.
National High Technology Zone. Available at: http://www.most.gov.cn/gxjscykfq/index.htm
Plan of the National Medium and Long-term Plan for the Development of Science and Technology (2006–2020). Available at: https://www.itu.int/en/ITU-D/Cybersecurity/Documents/National_Strategies_Repository/China_2006.pdf
Le Maire fustige "le pillage de technologies" chinois et refuse des investissements (2018). Available at: https://www.challenges.fr/economie/le-maire-fustige-le-pillage-de-technologies-chinois-et-refuse-des-investissements_558913
Salikhova, Е. (2020). Turbonyani. LB.ua. Available at: https://lb.ua/economics/2020/02/25/450866_turbonyani.html
A new special drug project accompanies people's health. Available at: http://www.gov.cn/zhengce/2018-10/10/content_5329091.htm
State Council Press and Distribution Report "Made in China in 2025". Available at: http://www.china.com.cn/legal/2015-05/19/content_35606051.htm
Notice from the six print and distribution departments of the Pharmaceutical Industry Development Planning Guide. Available at: http://www.gov.cn/xinwen/2016-11/09/content_5130391.htm
State-supported high-tech industries. Available at: http://www.waizi.org.cn/law/6441.html
National High-tech Enterprise Certification Management Measures (latest version). Available at: http://www.gaoxinbutie.com/faq/480.html
Ministry of Finance, General Directorate of Taxation, Ministry of Science and Technology, Notification of an increase in the pre-tax deduction rate before taxes on research and development costs Tsai Shui (2018). No. 99. Available at: http://www.chinatax.gov.cn/n810341/n810755/c3754895/content.html
An announcement by the State Tax Administration on current tax policy issues regarding accelerated depreciation of fixed assets. Announcement No. 64 (2014). Available at: http://www.chinaacc.com/zyssfg/hu2014111718511263263436.shtml
Catalogue of Industries for Encouraging Foreign Investment (2019). Available at: https://www.pkulaw.com/en_law/2e6fab8549042788bdfb.html
Government Procurement Law of the People’s Republic of China (2014). Available at: http://fgw.yinchuan.gov.cn/fgzc/flfg/201812/t20181221_1224321.htm
Notice to the National Health Commission on the press and distribution of interim public procurement management measures. Guowei Caifafa (2018). No. 17. Available at: http://www.waizi.org.cn/doc/38884.html
Public Procurement in China: European Business Experiences Competing for Public Contracts in China (2011). Public Procurement Study. European Chamber. Available at: https://cbi.typepad.com/files/euccc-public-procurement-in-china-april-2011.pdf
Pfeffer, J., Salancik, G. R. (1978). The External Control of Organizations: A Resource Dependence Perspective. University of Illinois at Urbana-Champaign's Academy for Entrepreneurial Leadership Historical Research Reference in Entrepreneurship. Available at: https://ssrn.com/abstract=1496213
Burt, R. S. (1992). Structural Holes: The Social Structure of Competition. University of Illinois at Urbana-Champaign's Academy for Entrepreneurial Leadership Historical Research Reference in Entrepreneurship. Available at: https://ssrn.com/abstract=1496205
Veblen, T. (1921). The Engineers & the Price System. New York: B. W. Huebsch, inc., 169.
Gerschenkron, A. (1962). Economic Backwardness in Historical Perspective. The Belknap Press of Harvard University, 456.
Hui, J. (2017). American export control, technology spillover and innovation of Chinese pharmaceutical Industry. Pakistan Journal of Pharmaceutical Sciences, 30 (3), 1151–1155. Available at: https://pubmed.ncbi.nlm.nih.gov/28671099/
McGregor, J. (2010). China’s Drive for ‘Indigenous Innovation’: A Web of Industrial Policies. US Chamber of Commerce. Available at: https://www.uschamber.com/sites/default/files/documents/files/100728chinareport_0_0.pdf
Schweitzer, S. O., Lu Zhong, J. (2018). Pharmaceutical Economics and Policy: Perspectives, Promises, and Problems. Oxford University Press, 408. doi: http://doi.org/10.1093/oso/9780190623784.001.0001
A Joint Survey: Supply Chain Strategies Under the Impact of COVID-19 of Large American Companies Operating in China (2020). Available at: https://www.amcham-shanghai.org/en/article/joint-survey-supply-chain-strategies-underimpact-covid-19-large-american-companies
Regulation (EU) 2019/452 of the European Parliament and of the Council of 19 March 2019 establishing a framework for the screening of foreign direct investments into the Union. Available at: https://eur-lex.europa.eu/eli/reg/2019/452/oj?locale=en
Copyright (c) 2020 Daria Honcharenko
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the CREATIVE COMMONS copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons Attribution License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
